Background

• Marijuana, hemp, and cannabis are common names for plants of the genus Cannabis. The term hemp is often used for cannabis strains grown specifically for production of paper, rope, and cloth. Other cannabis strains are used to make recreational and medicinal drugs. The major difference between the main types of cannabis plants is the amount of the psychoactive compound tetrahydrocannabinol (THC) they contain.
• Cannabis has been used medicinally for approximately 5,000 years. The most widely used components of the herb in traditional medicine are the seed and seed oil. Cannabis sativa is widely used recreationally (inhaled or taken by mouth) to achieve increased feelings of well-being.
• Cannabis has been studied for the treatment of a number of conditions, including eczema, epilepsy, chronic pain, insomnia, and symptoms of multiple sclerosis. The most significant benefits have been found in the treatment of chronic pain and symptoms of multiple sclerosis.
• The two most studied cannabinoid compounds of Cannabis sativa are the psychoactive tetrahydrocannabinol (THC) and the nonpsychoactive cannabidiol (CBD).

References

• Aggarwal SK, Carter GT, Sullivan MD, et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 2009;5(3):153-68.
  View Abstract
• Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112(3):299-306.
  View Abstract
• Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007;23(1):17-24.
  View Abstract
• Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290(13):1757-62.
  View Abstract
• Lozano I. [Therapeutic use of Cannibis Sativa L. in Arab medicine.] Asclepio 1997;49(2):199-208.
  View Abstract
• Martín-Sánchez E, Furukawa TA, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009;10(8):1353-68.
  View Abstract
• Perez J, Ribera MV. Managing neuropathic pain with Sativex: a review of its pros and cons. Expert Opin Pharmacother 2008;9(7):1189-95.
  View Abstract
• Perras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005;(72):1-4.
  View Abstract
• Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009;6(4):713-37.
  View Abstract
• Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29(9):2068-79.
  View Abstract
• Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9.
  View Abstract
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329(7460):253.
  View Abstract
• Turcotte D, Le Dorze JA, Esfahani F, et al. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother 2010;11(1):17-31.
  View Abstract
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10(4):434-41.
  View Abstract
• Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17(1):21-9.
  View Abstract